PharmaSGP Holding SE

XTRA:PSG Stock Report

Market Cap: €299.8m

PharmaSGP Holding Future Growth

Future criteria checks 3/6

PharmaSGP Holding is forecast to grow earnings and revenue by 13.6% and 7.3% per annum respectively. EPS is expected to grow by 13.5% per annum. Return on equity is forecast to be 38.1% in 3 years.

Key information

13.6%

Earnings growth rate

13.5%

EPS growth rate

Pharmaceuticals earnings growth21.6%
Revenue growth rate7.3%
Future return on equity38.1%
Analyst coverage

Low

Last updated04 Dec 2024

Recent future growth updates

Recent updates

PharmaSGP Holding's (ETR:PSG) Performance Is Even Better Than Its Earnings Suggest

Dec 06
PharmaSGP Holding's (ETR:PSG) Performance Is Even Better Than Its Earnings Suggest

Shareholders Will Be Pleased With The Quality of PharmaSGP Holding's (ETR:PSG) Earnings

May 06
Shareholders Will Be Pleased With The Quality of PharmaSGP Holding's (ETR:PSG) Earnings

Some Shareholders Feeling Restless Over PharmaSGP Holding SE's (ETR:PSG) P/E Ratio

Mar 02
Some Shareholders Feeling Restless Over PharmaSGP Holding SE's (ETR:PSG) P/E Ratio

PharmaSGP Holding SE Just Beat Revenue Estimates By 25%

Dec 02
PharmaSGP Holding SE Just Beat Revenue Estimates By 25%

One Analyst Just Shaved Their PharmaSGP Holding SE (ETR:PSG) Forecasts Dramatically

Feb 16
One Analyst Just Shaved Their PharmaSGP Holding SE (ETR:PSG) Forecasts Dramatically

We Think PharmaSGP Holding's (ETR:PSG) Statutory Profit Might Understate Its Earnings Potential

Jan 26
We Think PharmaSGP Holding's (ETR:PSG) Statutory Profit Might Understate Its Earnings Potential

Do Institutions Own PharmaSGP Holding SE (ETR:PSG) Shares?

Dec 04
Do Institutions Own PharmaSGP Holding SE (ETR:PSG) Shares?

Earnings and Revenue Growth Forecasts

XTRA:PSG - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261332529342
12/31/20251232226312
12/31/20241142024322
9/30/2024114192930N/A
6/30/2024110182122N/A
3/31/2024107182628N/A
12/31/2023101162627N/A
9/30/202398152526N/A
6/30/202394142223N/A
3/31/202389132828N/A
12/31/202286122425N/A
9/30/202283113435N/A
6/30/20228111-6419N/A
3/31/20227411-7112N/A
12/31/20216511-7112N/A
9/30/2021618-89-6N/A
6/30/202156888N/A
3/31/20215991213N/A
12/31/202063111515N/A
9/30/202065161819N/A
6/30/202065171718N/A
3/31/202064172020N/A
12/31/201963171718N/A
12/31/2018611588N/A
12/31/20175312N/A14N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PSG's forecast earnings growth (13.6% per year) is above the savings rate (1%).

Earnings vs Market: PSG's earnings (13.6% per year) are forecast to grow slower than the German market (20.6% per year).

High Growth Earnings: PSG's earnings are forecast to grow, but not significantly.

Revenue vs Market: PSG's revenue (7.3% per year) is forecast to grow faster than the German market (5.8% per year).

High Growth Revenue: PSG's revenue (7.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PSG's Return on Equity is forecast to be high in 3 years time (38.1%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/17 17:10
End of Day Share Price 2024/12/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PharmaSGP Holding SE is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gerhard OrgonasBerenberg
Charles WestonRBC Capital Markets
Jack Reynolds-ClarkRBC Capital Markets